{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:20:57Z","timestamp":1777530057245,"version":"3.51.4"},"reference-count":61,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Patients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a challenge to the multidisciplinary healthcare team due to the complexity of the pathophysiology of their disease state and PAH-specific medication considerations. Pulmonary arterial hypertension is a progressive disease that may lead to death as a result of right ventricular (RV) failure. During acute on chronic RV failure it is critical to decrease the pulmonary vascular resistance with the goal of improving RV function and prognosis; therefore, aggressive PAH-treatment based on disease risk stratification is essential. Pulmonary arterial hypertension treatment for acute on chronic RV failure can be impacted by end-organ damage, hemodynamic instability, drug interactions, and PAH medications dosage and delivery. Sotatercept, a first in class activin signaling inhibitor that works on the bone morphogenetic protein\/activin pathway is on track for Food and Drug Administration approval for the treatment of PAH based on results of recent trials in where the medication led to clinical and hemodynamic improvements, even when added to traditional PAH-specific therapies. The purpose of this review is to highlight important considerations when starting or continuing sotatercept in patients admitted to the hospital with PAH.<\/jats:p>","DOI":"10.1177\/10742484231225310","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T01:20:08Z","timestamp":1708046408000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-4104","authenticated-orcid":false,"given":"Heather","family":"Torbic","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano R.","family":"Tonelli","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"bibr1-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"bibr2-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018"},{"key":"bibr3-10742484231225310","volume-title":"Adempas (riociguat) [package insert]","year":"2018"},{"key":"bibr4-10742484231225310","volume-title":"Tyvaso (treprostinil) inhalation [package insert]","year":"2017"},{"key":"bibr5-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0300"},{"key":"bibr6-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00148310"},{"key":"bibr7-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.949933"},{"key":"bibr8-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.03.028"},{"key":"bibr9-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"bibr10-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"bibr11-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061501"},{"key":"bibr12-10742484231225310","unstructured":"Liu J, Pearsall RS, Andre P, Kumar R, Li G. Sotatercept Analog RAP-011 Alleviates Cardiopulmonary Remodeling and Inflammation in a Model of Heritable PAH Arising from Bmpr2 Haploinsufficiency. TP85 TP085 A HARD DAY?S NIGHT \u2013 NOVEL MOLECULAR MECHANISMS AND TREATMENT OPTIONS IN PAH AND BEYOND: FROM PULMONARY VASCULATURE TO RV. p. A3657-A."},{"issue":"1","key":"bibr13-10742484231225310","volume":"138","author":"Joshi SR","year":"2018","journal-title":"Circulation"},{"key":"bibr14-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2929-9"},{"key":"bibr15-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12835"},{"key":"bibr16-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30002-4"},{"key":"bibr17-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.08.001"},{"key":"bibr18-10742484231225310","unstructured":"Merck & Co. I. Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH) 2023 [Available from: https:\/\/www.merck.com\/news\/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-pah\/."},{"key":"bibr19-10742484231225310","unstructured":"Risbano MG, Frantz RP, Manimaran S, Lu J, Rischard F. The SPECTRA Study: A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study to Assess the Effects of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH). D3 D003 COME TOGETHER \u2013 CLINICAL ADVANCES IN PULMONARY HYPERTENSION: LESSONS FROM BEST ABSTRACTS. p. A1187-A."},{"key":"bibr20-10742484231225310","unstructured":"Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (MOONBEAM) (MOONBEAM). https:\/\/clinicaltrials.gov\/study\/NCT05587712"},{"key":"bibr21-10742484231225310","unstructured":"A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007\/A011-16) (CADENCE). https:\/\/clinicaltrials.gov\/study\/NCT04945460"},{"key":"bibr22-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213558"},{"key":"bibr23-10742484231225310","unstructured":"Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005\/A011-13) (HYPERION). https:\/\/clinicaltrials.gov\/study\/NCT04811092"},{"key":"bibr24-10742484231225310","unstructured":"A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006\/ZENITH) (ZENITH). https:\/\/clinicaltrials.gov\/study\/NCT04896008"},{"key":"bibr25-10742484231225310","unstructured":"A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004\/\u200bA011-12) (SOTERIA). https:\/\/clinicaltrials.gov\/study\/NCT04796337"},{"key":"bibr26-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01107-2023"},{"key":"bibr27-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.05.030"},{"key":"bibr28-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.OA739"},{"key":"bibr29-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01347-2022"},{"key":"bibr30-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01070-2023"},{"key":"bibr31-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211053994"},{"key":"bibr32-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00002-2022"},{"key":"bibr33-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00046-2021"},{"key":"bibr34-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-015-9514-7"},{"key":"bibr35-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0662CI"},{"key":"bibr36-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0092-2017"},{"key":"bibr37-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019838110"},{"key":"bibr38-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.2002.02324.x"},{"key":"bibr39-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1378\/chest.98.5.1102"},{"key":"bibr40-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200211000-00024"},{"key":"bibr41-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200404000-00040"},{"key":"bibr42-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217702401"},{"key":"bibr43-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217753352"},{"key":"bibr44-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1177\/1074248419877409"},{"key":"bibr45-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000280433.74246.9E"},{"key":"bibr46-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00494-5"},{"key":"bibr47-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015608865"},{"key":"bibr48-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1396"},{"key":"bibr49-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.160"},{"key":"bibr50-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-015-0288-y"},{"key":"bibr51-10742484231225310","volume-title":"Veletri (epoprostenol) [package insert]","year":"2018"},{"key":"bibr52-10742484231225310","volume-title":"Flolan (epoprostenol) [package insert]","year":"2018"},{"key":"bibr53-10742484231225310","volume-title":"Remodulin (treprostinil) injection [package insert]","year":"2018"},{"key":"bibr54-10742484231225310","first-page":"479730","volume":"2013","author":"Case J","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"bibr55-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2014.07.012"},{"key":"bibr56-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.660"},{"key":"bibr57-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0337-8"},{"key":"bibr58-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12054"},{"key":"bibr59-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08082.x"},{"key":"bibr60-10742484231225310","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"bibr61-10742484231225310","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2011.23.S1.S30"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484231225310","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10742484231225310","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484231225310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:41:49Z","timestamp":1777394509000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10742484231225310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":61,"alternative-id":["10.1177\/10742484231225310"],"URL":"https:\/\/doi.org\/10.1177\/10742484231225310","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"10742484231225310"}}